Rani Therapeutics Holdings, Inc.'s (NASDAQ:RANI) largest shareholders are individual investors who were rewarded as market cap surged US$12m last week
In This Article:
Key Insights
-
Rani Therapeutics Holdings' significant individual investors ownership suggests that the key decisions are influenced by shareholders from the larger public
-
A total of 7 investors have a majority stake in the company with 50% ownership
-
Using data from analyst forecasts alongside ownership research, one can better assess the future performance of a company
A look at the shareholders of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) can tell us which group is most powerful. With 44% stake, individual investors possess the maximum shares in the company. Put another way, the group faces the maximum upside potential (or downside risk).
As a result, individual investors collectively scored the highest last week as the company hit US$149m market cap following a 18% gain in the stock.
In the chart below, we zoom in on the different ownership groups of Rani Therapeutics Holdings.
View our latest analysis for Rani Therapeutics Holdings
What Does The Institutional Ownership Tell Us About Rani Therapeutics Holdings?
Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.
We can see that Rani Therapeutics Holdings does have institutional investors; and they hold a good portion of the company's stock. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Rani Therapeutics Holdings, (below). Of course, keep in mind that there are other factors to consider, too.
We note that hedge funds don't have a meaningful investment in Rani Therapeutics Holdings. Looking at our data, we can see that the largest shareholder is South Lake Management LLC with 41% of shares outstanding. The Vanguard Group, Inc. is the second largest shareholder owning 2.4% of common stock, and Pivotal BioVenture Partners LLC holds about 1.7% of the company stock. In addition, we found that Talat Imran, the CEO has 0.6% of the shares allocated to their name.
We also observed that the top 7 shareholders account for more than half of the share register, with a few smaller shareholders to balance the interests of the larger ones to a certain extent.
Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. Quite a few analysts cover the stock, so you could look into forecast growth quite easily.